Literature DB >> 18061231

Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.

Indresh K Srivastava1, Elaine Kan, Yide Sun, Victoria A Sharma, Jimna Cisto, Brian Burke, Ying Lian, Susan Hilt, Zohar Biron, Karin Hartog, Leonidas Stamatatos, Ruben Diaz-Avalos, R Holland Cheng, Jeffrey B Ulmer, Susan W Barnett.   

Abstract

We previously reported that an envelope (Env) glycoprotein immunogen (o-gp140DeltaV2SF162) containing a partial deletion in the second variable loop (V2) derived from the R5-tropic HIV-1 isolate SF162 partially protected vaccinated rhesus macaques against pathogenic SHIV(SF162P4) virus. Extending our studies to subtype C isolate TV1, we have purified o-gp140DeltaV2TV1 (subtype C DeltaV2 trimer) to homogeneity, performed glycosylation analysis, and determined its ability to bind CD4, as well as a panel of well-characterized neutralizing monoclonal antibodies (mAb). In general, critical epitopes are preserved on the subtype C DeltaV2 trimer; however, we did not observe significant binding for the b12 mAb. The molecular mass of subtype C DeltaV2 trimer was found to be 450 kDa, and the hydrodynamic radius was found to be 10.87 nm. Our data suggest that subtype C DeltaV2 trimer binds to CD4 with an affinity comparable to o-gp140DeltaV2SF162 (subtype B DeltaV2 trimer). Using isothermal titration calorimetric (ITC) analysis, we demonstrated that all three CD4 binding sites (CD4-BS) in both subtype C and B trimers are exposed and accessible. However, compared to subtype B trimer, the three CD4-BS in subtype C trimer have different affinities for CD4, suggesting a cooperativity of CD4 binding in subtype C trimer but not in subtype B trimer. Negative staining electron microscopy of the subtype C DeltaV2 trimer has demonstrated that it is in fact a trimer. These results highlight the importance of studying subtype C Env, and also of developing appropriate subtype C-specific reagents that may be used for better immunological characterization of subtype C Env for developing an AIDS vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061231     DOI: 10.1016/j.virol.2007.10.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

1.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

3.  Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example.

Authors:  Quinn K T Ng; Marie K Sutton; Pan Soonsawad; Li Xing; Holland Cheng; Tatiana Segura
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

4.  Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites.

Authors:  Bin Yu; Dora P A J Fonseca; Sara M O'Rourke; Phillip W Berman
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

5.  Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.

Authors:  Juan García-Arriaza; Beatriz Perdiguero; Jonathan Heeney; Michael Seaman; David C Montefiori; Celia Labranche; Nicole L Yates; Xiaoying Shen; Georgia D Tomaras; Guido Ferrari; Kathryn E Foulds; Adrian McDermott; Shing-Fen Kao; Mario Roederer; Natalie Hawkins; Steve Self; Jiansheng Yao; Patrick Farrell; Sanjay Phogat; Jim Tartaglia; Susan W Barnett; Brian Burke; Anthony Cristillo; Deborah Weiss; Carter Lee; Karen Kibler; Bert Jacobs; Benedikt Asbach; Ralf Wagner; Song Ding; Giuseppe Pantaleo; Mariano Esteban
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

6.  Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding.

Authors:  Carlos G Moscoso; Yide Sun; Selina Poon; Li Xing; Elaine Kan; Loïc Martin; Dominik Green; Frank Lin; Anders G Vahlne; Susan Barnett; Indresh Srivastava; R Holland Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

7.  Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Authors:  Karen V Kibler; Benedikt Asbach; Beatriz Perdiguero; Juan García-Arriaza; Nicole L Yates; Robert Parks; Sherry Stanfield-Oakley; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Mario Roederer; Kathryn E Foulds; Donald N Forthal; Michael S Seaman; Steve Self; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan Barnett; Anthony D Cristillo; Deborah Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Ralf Wagner; Giuseppe Pantaleo; Bertram L Jacobs
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

8.  Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

Authors:  Willy M Bogers; Herman Oostermeijer; Petra Mooij; Gerrit Koopman; Ernst J Verschoor; David Davis; Jeffrey B Ulmer; Luis A Brito; Yen Cu; Kaustuv Banerjee; Gillis R Otten; Brian Burke; Antu Dey; Jonathan L Heeney; Xiaoying Shen; Georgia D Tomaras; Celia Labranche; David C Montefiori; Hua-Xin Liao; Barton Haynes; Andrew J Geall; Susan W Barnett
Journal:  J Infect Dis       Date:  2014-09-18       Impact factor: 5.226

9.  Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

Authors:  Rachmat Hidajat; Seraphin Kuate; David Venzon; Vaniambadi Kalyanaraman; Irene Kalisz; James Treece; Ying Lian; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2010-04-09       Impact factor: 3.641

10.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.